Safety and Effectiveness of PRI-724 for Hepatitis C or B Virus Derived Liver Cirrhosis

Inclusion criteria

• ✓. Patients with serum HCV-RNA positive or HCV antibody positive
• ✓. Patients with serum HBV-DNA positive or HBs antigen positive
• ✓. confirmed liver cirrhosis by liver biopsy performed in the screening period patients who received diagnosis
• ✓. Patients who have not reached SVR \* with DAA therapy
• ✓. Patients who are difficult to implement DAA therapy
• ✓. Patients who have been over 24 weeks after achieving SVR \* with DAA therapy In case of HBV cirrhosis;
• ✓. Patients who have been at least 24 weeks since the start of administration of Nucleotide analogue \* SVR is SVR 12 (sustained virological response at 12 weeks after the end of administration).